Prevalence and Characteristics of Potential QT ‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs

ABSTRACT Background Patients with cancer are at increased risk of QT interval prolongation because of polypharmacy and concomitant use of QT‐prolonging medications. Drug–drug interactions (DDIs) may further increase this risk. Outpatient electrocardiogram (ECG) monitoring appears to be underused among patients receiving oral anticancer drugs (OADs). Our study objective was to evaluate the prevalence and characteristics of potential QT interval–prolonging drug–drug interactions (QT pDDIs) in patients with cancer receiving OAD therapy. Methods A retrospective observational study was conducted using electronic health record data from 3697 patients with advanced cancer. Patients who received at least one OAD were included in the analysis. Potential QT‐related DDIs were identified through overlap prescriptions of concomitant medications associated with QT prolongation and/or Cytochrome P450‐ (CYP‐) or drug transporter‐mediated interactions during OAD exposure. Descriptive analyses were performed to characterize the prevalence and types of QT pDDIs. Results Of the 3697 patients, 1732 (46.8%) received at least one OAD and were included in the analysis. Of these, 17.1% experienced at least one QT pDDI. Among those patients, 47.5% experienced PD‐QT pDDIs only, 21.2% experienced PK‐QT pDDIs only, and 31.3% experienced both PD‐ and PK‐QT pDDIs during OAD exposure. Concurrent PD and PK mechanisms occurred simultaneously in 30.6% of patients with QT‐pDDIs. Approximately 48% of identified QT pDDIs involved at least one OAD, most commonly pazopanib (13.5%), palbociclib (11.3%), and vandetanib (8.4%). Conclusion QT pDDIs were common among patients with cancer receiving OADs, highlighting the importance of comprehensive DDI screening, careful medication review, and enhanced cardiac monitoring strategies in oncology practice.

Authors

Institutions

Publication Details

Journal
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Published
2026-11-15
DOI
https://doi.org/10.1002/phar.70217
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prevalence and Characteristics of Potential QT ‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs

Todd C. Skaar, Rohan Maniar, James Edward Tisdale, Tyler Shugg et al.
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Chemotherapy-induced cardiotoxicity and mitigation
article

Prevalence and Characteristics of Potential QT ‐Interval‐Prolonging Drug–Drug Interactions in Patients Receiving Oral Anticancer Drugs

Todd C. Skaar, Rohan Maniar, James Edward Tisdale, Tyler Shugg, Fatimah Alhurayri, Sara K. Quinney, Shadia Ibrahim Jalal, Steven M. Bray, Islam Rasem Younis, Zeruesenay Desta, Theodore F. Logan
article en

Abstract

ABSTRACT Background Patients with cancer are at increased risk of QT interval prolongation because of polypharmacy and concomitant use of QT‐prolonging medications. Drug–drug interactions (DDIs) may further increase this risk. Outpatient electrocardiogram (ECG) monitoring appears to be underused among patients receiving oral anticancer drugs (OADs). Our study objective was to evaluate the prevalence and characteristics of potential QT interval–prolonging drug–drug interactions (QT pDDIs) in patients with cancer receiving OAD therapy. Methods A retrospective observational study was conducted using electronic health record data from 3697 patients with advanced cancer. Patients who received at least one OAD were included in the analysis. Potential QT‐related DDIs were identified through overlap prescriptions of concomitant medications associated with QT prolongation and/or Cytochrome P450‐ (CYP‐) or drug transporter‐mediated interactions during OAD exposure. Descriptive analyses were performed to characterize the prevalence and types of QT pDDIs. Results Of the 3697 patients, 1732 (46.8%) received at least one OAD and were included in the analysis. Of these, 17.1% experienced at least one QT pDDI. Among those patients, 47.5% experienced PD‐QT pDDIs only, 21.2% experienced PK‐QT pDDIs only, and 31.3% experienced both PD‐ and PK‐QT pDDIs during OAD exposure. Concurrent PD and PK mechanisms occurred simultaneously in 30.6% of patients with QT‐pDDIs. Approximately 48% of identified QT pDDIs involved at least one OAD, most commonly pazopanib (13.5%), palbociclib (11.3%), and vandetanib (8.4%). Conclusion QT pDDIs were common among patients with cancer receiving OADs, highlighting the importance of comprehensive DDI screening, careful medication review, and enhanced cardiac monitoring strategies in oncology practice.

Pharmacotherapy The Journal of Human Pharmacology and Drug TherapyVol. 46(12)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Ivy Tech Community College of Indiana (US), Purdue University West Lafayette (US), Indiana University Indianapolis (US), Indiana University School of Medicine (US), Imam Abdulrahman Bin Faisal University (SA)
Chemotherapy-induced cardiotoxicity and mitigation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon